Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio

Pharmacoeconomics. 2000 Apr;17(4):339-49. doi: 10.2165/00019053-200017040-00004.

Abstract

The aim of this article is to consider Bayesian and frequentist inference methods for measures of incremental cost effectiveness in data obtained via a clinical trial. The most useful measure is the cost-effectiveness (C/E) acceptability curve. Recent publications on Bayesian estimation have assumed a normal posterior distribution, which ignores uncertainty in estimated variances, and suggest unnecessarily complicated methods of computation. We present a simple Bayesian computation for the C/E acceptability curve and a simple frequentist analogue. Our approach takes account of errors in estimated variances, resulting in calculations that are based on distributions rather than normal distributions. If inference is required about the C/E ratio, we argue that the standard frequentist procedures give unreliable or misleading inferences, and present instead a Bayesian interval.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / economics
  • Antirheumatic Agents / therapeutic use
  • Bayes Theorem*
  • Clinical Trials as Topic / economics
  • Cost-Benefit Analysis*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Sialoglycoproteins / economics
  • Sialoglycoproteins / therapeutic use
  • Survival Rate
  • Systemic Inflammatory Response Syndrome / drug therapy
  • Systemic Inflammatory Response Syndrome / economics
  • Systemic Inflammatory Response Syndrome / mortality

Substances

  • Antirheumatic Agents
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Sialoglycoproteins